Collaborative Efforts Will Drive Antibiotic Discovery

2 initiatives tackle different aspects of the war against drug-resistant superbugs

Navigate to:

Collaborative Efforts Will Drive Antibiotic Discovery
Antibiotics
Getty Images

Effective November 18, 2021, Pew transferred all SPARK data to The University of Queensland’s Community for Open Antimicrobial Drug Discovery (CO-ADD). Please visit spark.co-add.org or contact [email protected].

Scientists have long faced difficult challenges as they work to find and design antibiotics that can defeat some of the world’s toughest superbugs, Gram-negative bacteria. Meanwhile, the medical and public health threat posed by these increasingly drug-resistant pathogens is getting worse.

Experts agree that tackling this problem requires targeted, collaborative efforts around the globe, along with other key tactics outlined in The Pew Charitable Trusts’ “A Scientific Roadmap for Antibiotic Discovery.” To that end, Pew and LifeArc, a medical research charity based in the United Kingdom, are working on separate but complementary initiatives.

In September, Pew launched SPARK, the Shared Platform for Antibiotic Research and Knowledge, an information-sharing platform intended to help fill the knowledge gaps impeding antibiotic innovation. The platform, which is publicly available at no cost, brings together antibiotic discovery data and cutting-edge analytics to help scientists from around the world generate and share new hypotheses.

The collaborative research enabled by SPARK will focus on overcoming the unique challenges of finding drugs that can enter and remain inside Gram-negative bacteria. In the lead-up to the launch, Pew engaged leaders in the field to shape SPARK’s development, and LifeArc scientists were among these key experts.

While Pew’s SPARK provides the information-sharing tool to spur antibiotic discovery, LifeArc is generating data that can be integrated into the platform to enrich the resource for researchers. As part of its collaboration with Canada’s Centre for Drug Research and Development (CDRD), LifeArc is conducting several studies to help measure the concentration of compounds inside Gram-negative bacteria.

One study with CDRD will investigate the physical characteristics of drug compounds that can penetrate the cell wall of a wide range of multidrug-resistant bacteria. By determining the most valuable biophysical properties of these compounds and combining these findings with other work, researchers can maximize the potential for developing new antibiotics that work in the clinic.

LifeArc plans to feed the data generated from its studies into SPARK to help inform researchers’ hypotheses about the properties of compounds that penetrate Gram-negative bacteria. Ultimately these data can be used in the design of new antibiotics.

Overcoming the barriers blocking antibiotic innovation will not happen overnight, but these initiatives each focus on an important component of the antibiotic discovery puzzle. LifeArc provides the puzzle pieces, while Pew brings the scientists to the table to help fit them together.

By sharing information and working together, the antibiotic discovery community can systematically begin to understand the key molecular features of compounds that can overcome the defenses of the toughest bacteria.

Kathy Talkington is director of The Pew Charitable Trusts’ antibiotic resistance project. Andy Merritt manages a team of chemists who carry out early stage drug discovery at LifeArc.

Spotlight on Mental Health

Vials
Vials
Report

A Scientific Roadmap for Antibiotics

Quick View
Report

In recent decades, the discovery and development of new antibiotics have slowed dramatically as scientific barriers to drug discovery, regulatory challenges, and diminishing returns on investment have led major drug companies to scale back or abandon their antibiotic research.

SPARK
SPARK

The Shared Platform for Antibiotic Research and Knowledge (SPARK)

Quick View

One of the barriers to discovering new antibiotics is a lack of information sharing. Despite a long history of antibiotic research, scientists often cannot build on past work, or avoid repeating mistakes, because research findings are scattered across the academic literature or not publicly available.

Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.

Explore Pew’s new and improved
Fiscal 50 interactive

Your state's stats are more accessible than ever with our new and improved Fiscal 50 interactive:

  • Maps, trends, and customizable charts
  • 50-state rankings
  • Analysis of what it all means
  • Shareable graphics and downloadable data
  • Proven fiscal policy strategies

Explore

Welcome to the new Fiscal 50

Key changes include:

  • State pages that help you keep track of trends in your home state and provide national and regional context.
  • Interactive indicator pages with highly customizable and shareable data visualizations.
  • A Budget Threads feature that offers Pew’s read on the latest state fiscal news.

Learn more about the new and improved Fiscal 50.